Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
19.1M
-
Shares change
-
+4.14M
-
Total reported value, excl. options
-
$31.4M
-
Value change
-
+$6.9M
-
Put/Call ratio
-
0.02
-
Number of buys
-
42
-
Number of sells
-
-7
-
Price
-
$1.65
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q2 2023
61 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2023.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.1M shares
of 120M outstanding shares and own 15.86% of the company stock.
Largest 10 shareholders include Bratton Capital Management, L.P. (9.81M shares), VANGUARD GROUP INC (1.56M shares), RENAISSANCE TECHNOLOGIES LLC (1.23M shares), ARMISTICE CAPITAL, LLC (1.16M shares), Vahanian & Associates Financial Planning Inc. (725K shares), Bracebridge Capital, LLC (429K shares), GEODE CAPITAL MANAGEMENT, LLC (411K shares), BlackRock Inc. (406K shares), Walleye Capital LLC (404K shares), and MILLENNIUM MANAGEMENT LLC (323K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.